Prexton Therapeutics
Prexton Therapeutics is a privately held Swiss clinical-stage biopharmaceutical company founded in 2012 in Plan-les-Ouates, Switzerland, developing innovative drug candidates with a lean team of 1-10 employees.
- Company typePrivate
- Founded2026
- HeadquartersPlan-les-ouates, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prexton Therapeutics does
Prexton Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Plan-les-Ouates, in the Geneva life sciences cluster of Switzerland. The company's stated mission is to develop innovative drugs intended to improve patients' quality of life, positioning it as a small-molecule therapeutic developer rather than a platform, services, or diagnostics business. The firm operates with a very lean headcount of 1-10 employees, consistent with a venture-backed preclinical or early-clinical biotech that outsources most R&D activities.
The company has financed its operations through three recorded equity rounds between 2013 and 2017, totaling roughly $41 million. The capital base came from a syndicate of European life sciences specialists: Eclosion SA at founding, followed by Ysios Capital (lead), M Ventures, and Sunstone Life Science Ventures in a 2015 Series 2, and then a 2017 Series 2 of approximately $31 million led by Forbion Capital Partners and Seroba Life Sciences. No product candidates, pipeline indications, technology platforms, partnership agreements, customers, or revenue figures are disclosed in the available data, and no activity is recorded after February 2017, leaving the current operating picture materially incomplete.
Commercially, Prexton's revenue model is not articulated in the source data. As a drug developer, the implied mechanics would be eventual out-licensing, milestone payments, royalties, or an exit via acquisition, but none of these have been disclosed. There is no published pricing, GTM motion, customer segmentation, or distribution footprint. The investment-relevant takeaway is that Prexton is a thinly documented, small-cap, Switzerland-domiciled biotech whose remaining value, if any, sits in undisclosed clinical assets and IP that the available sources do not enumerate.
Prexton Therapeutics firmographics
Firmographics- Name
- Prexton Therapeutics
- Legal name
- CAS Analytical Genprice Lab
- Website
- https://prextontherapeutics.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prexton Therapeutics is a privately held Swiss clinical-stage biopharmaceutical company founded in 2012 in Plan-les-Ouates, Switzerland, developing innovative drug candidates with a lean team of 1-10 employees.
- Ownership category
- akta.pro rank
Prexton Therapeutics industry classification
Industry- Product category
- Neurological Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology) (HLAIALAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Prexton Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Prexton Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Prexton Therapeutics product offering
Product offeringCore offering
Prexton Therapeutics is a clinical-stage biopharmaceutical company developing innovative drugs intended to improve patients' quality of life. The company's mission centers on pharmaceutical research and novel drug discovery targeting neurological and central nervous system (CNS) disorders, advancing compounds from research through clinical development.
Differentiator
Problem solved
Functional benefit
Companies that use Prexton Therapeutics
Customer profileIdeal customer profiles1 record
Prexton Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Prexton Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Prexton Therapeutics competitors and assessment
Company assessmentDirect peers
- Sage Therapeutics: US-based clinical-stage CNS specialty biopharma developing innovative therapies for neurological and psychiatric disorders. Highly comparable in therapeutic focus (CNS specialty pharma) and development stage to Prexton.
- Axsome Therapeutics: US clinical-stage CNS biopharma developing novel therapies for neurological and psychiatric conditions. Comparable as a focused mid-cap CNS specialty drug developer with similar strategic positioning.
- Karuna Therapeutics: Clinical-stage CNS biopharma developing innovative therapies for psychiatric and neurological disorders. Comparable in CNS specialty focus, clinical-stage maturity, and Big Pharma acquisition trajectory (acquired by Bristol Myers Squibb).
- Cerevel Therapeutics: Clinical-stage CNS biopharma developing therapies for Parkinson's disease, epilepsy, and other neuroscience disorders. Direct therapeutic peer with shared focus on neurology specialty drug development.
- Newron Pharmaceuticals: Italy/Switzerland-based clinical-stage CNS specialty biopharma developing therapies for Parkinson's disease and other neurological disorders. Direct therapeutic and geographic peer to Prexton, with overlapping Parkinson's-focused R&D.
Broad incumbents
- Acadia Pharmaceuticals: Commercial-stage CNS specialty biopharma focused on neurological and psychiatric disorders, including Parkinson's-related indications. Comparable as a CNS-focused commercializer with adjacent therapeutic overlap.
- Roche: Swiss-headquartered global pharmaceutical company with a substantial CNS/neuroscience R&D presence in the Basel-Geneva corridor where Prexton is located. Provides regional and Big Pharma context for potential partnership or acquirer dynamics.
- Lundbeck: Danish CNS specialty pharmaceutical company and direct acquirer of Prexton Therapeutics in 2018. Comparable as a focused neurology/CNS drug developer and commercializer, providing a benchmark for the strategic exit pathway Prexton ultimately pursued.
Regional players
- Bial - Portela & Cª: Portuguese specialty pharmaceutical company with significant CNS franchise including Parkinson's therapies. Comparable as a European CNS-focused specialty pharma with overlapping disease focus, though primarily commercial-stage.
Others
- Forbion Capital Partners: Lead investor in Prexton's 2017 Series B and a leading European life sciences VC with deep CNS portfolio. Included as an ecosystem comparator illustrating the syndicate quality and providing context for benchmarking against other Forbion-backed CNS companies.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat2 records
Key highlights5 records
Customer concentration
Prexton Therapeutics social profiles
Digital presencePrexton Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prexton Therapeutics leadership team
Management profileNumber of profiles
Prexton Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prexton Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prexton Therapeutics
What does Prexton Therapeutics do?
Prexton Therapeutics is a clinical-stage biopharmaceutical company developing innovative drugs intended to improve patients' quality of life. The company's mission centers on pharmaceutical research and novel drug discovery targeting neurological and central nervous system (CNS) disorders, advancing compounds from research through clinical development.
Is Prexton Therapeutics a public or private company?
Prexton Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prexton Therapeutics founded?
Prexton Therapeutics was founded in 2026. It employs 1 to 10 people.
Where is Prexton Therapeutics based?
Prexton Therapeutics is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
Who are Prexton Therapeutics's main competitors?
Direct peers on record are Sage Therapeutics, Axsome Therapeutics, Karuna Therapeutics, Cerevel Therapeutics and Newron Pharmaceuticals. Broad incumbents are Acadia Pharmaceuticals, Roche and Lundbeck. Bial - Portela & Cª is listed as a regional player. Forbion Capital Partners is listed as an others.
Does Prexton Therapeutics have an API?
No public API is recorded for Prexton Therapeutics.
What industry is Prexton Therapeutics in?
Prexton Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 325412 and its SIC code is 2834.